PRINCETON, N.J. and NEW YORK, N.Y. (November 24, 2020) – Otsuka Pharmaceutical Development & Commercialization, Inc., announced an agreement with research experts from the Columbia University Irving Center Vagelos College of Physicians and Surgeons and Mailman School of Public Health to help support the epidemiological needs of Otsuka Global Pharmacovigilance (GPV) for products, enhanced
Activities will support the clinical development of Rugen’s potential first-in-class, orally administered drug candidate with initial clinical focus on treatment-resistant depression. PRINCETON, N.J. (October 30, 2020) – The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announced today that it has entered
Princeton, NEW JERSEY (October 21, 2020) – The Sozosei Foundation, a new philanthropy, has been launched to address the over-incarceration of people with mental illness and is convening an inaugural summit December 14-16 on this topic. Sozosei will also lead corporate social responsibility activities focused on disaster relief and local philanthropy, which will be centered on equity and
PRINCETON, N.J. & ROCKVILLE, Md. (September 29, 2020) – Otsuka America Pharmaceutical, Inc., (Otsuka) today announced that it is Great Place to Work-Certified™. Certification is a significant achievement. Using validated employee feedback gathered with Great Place to Work’s rigorous, data-driven “For All” methodology, Certification confirms at least seven out of 10 employees have a
Effort is part of the Accelerating Medicines Partnership to promote development of effective, targeted treatments.The National Institutes of Health is launching a new public-private partnership to meet the urgent need for early therapeutic interventions for people at risk of developing schizophrenia. Part of the Accelerating Medicines Partnership (AMP), AMP Schizophrenia (SCZ) brings together
PRINCETON, N.J. (August 25, 2020) – Otsuka America Pharmaceutical, Inc., (Otsuka) today announces that it has purchased the assets of Proteus Digital Health, Inc. (Proteus), including assets and intellectual property for its ingestible and wearable sensor technology. This milestone in the evolution of Otsuka’s digital medicine program strengthens its research and product development plan for
July 8, 2020 – Princeton, N.J. – Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announces the launch of NephU (www.nephu.org) (formerly PKDnetwork), a community and online resource library designed for healthcare professionals working in nephrology (study of the kidney) to help engage, collaborate, and share resources for people living with kidney disease. NephU